Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Giles Brindley & the 1983 Las Vegas Demonstration

The Lecture That Launched Injectable ED Therapy

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not Applicable (historical demonstration)

Reference only. Not medical advice.

What can go wrong

Intracavernosal injection carries a risk of priapism (prolonged, painful erection requiring emergency treatment), bruising, and fibrosis with repeated use. These risks were recognized through the era this demonstration helped launch. Historical/biographical entry; injectable therapy requires physician supervision.

This is something to take to a clinician. The Atlas can tell you what is known about giles brindley & the 1983 las vegas demonstration in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

At the 1983 Urodynamics Society meeting in Las Vegas, British physiologist Giles Skey Brindley presented the first effective drug therapy for erectile dysfunction: intracavernosal injection of smooth-muscle relaxants such as papaverine and phentolamine. To prove the effect was real and not psychogenic, Brindley had injected himself before the talk and, by accounts of attendees, displayed the result to the audience. The lecture became urology's most infamous, but it established intracavernosal injection, the standard before oral PDE5 inhibitors arrived.

A scientist proved his own discovery, on stage, in person.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Demonstrated intracavernosal injection therapy for ED
  • Established papaverine/phentolamine as pharmacologic erection inducers
  • Foundation for later FDA-approved injectables (alprostadil)

How it works

Papaverine and phentolamine relax penile arterial and trabecular smooth muscle when injected directly into the corpus cavernosum, increasing blood inflow and producing an erection independent of nervous-system arousal, the principle behind all intracavernosal injection therapy.

What people get wrong

  • Often saidThe Brindley lecture was just a stunt

    ActuallyThe theatrics are remembered, but it was the first public demonstration of effective pharmacologic ED therapy, a genuine medical milestone.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

Sir Giles Skey Brindley was a British physiologist and polymath known for work in vision, neuroprosthetics, and even bassoon acoustics. In the early 1980s he investigated drugs that could relax penile smooth muscle and induce erection directly, bypassing the need for psychological arousal. At the 1983 Urodynamics Society meeting in Las Vegas, he presented a slide series documenting his own penis in varying states of tumescence after self-injection of different doses of papaverine and phentolamine. According to a widely cited first-hand memoir by urologist Laurence Klotz (published in BJU International in 2005), Brindley, anticipating skepticism that the response was psychogenic, had injected himself in his hotel room beforehand, wore loose tracksuit trousers, and demonstrated the result directly to the stunned audience. However theatrical, the science was sound and historic: this was the first public description of an effective pharmacologic treatment for erectile dysfunction. Intracavernosal injection therapy became a mainstay of ED treatment through the 1980s and into the 1990s, and directly preceded the development of FDA-approved injectable alprostadil. When sildenafil arrived in 1998, oral therapy displaced injections as first-line, but Brindley's demonstration marked the moment ED became a treatable medical, rather than surgical or purely psychological, condition.

  1. 1970s-80sBrindley investigates smooth-muscle relaxants for erection
  2. 1983Las Vegas demonstration of papaverine/phentolamine injection
  3. 1980s-1990sIntracavernosal injection becomes standard ED therapy
  4. 1995FDA approves intracavernosal alprostadil (Caverject)
  5. 1998Oral sildenafil displaces injection as first-line therapy
  6. 2005Klotz publishes eyewitness memoir of the lecture

At a glance

Event
Urodynamics Society meeting, Las Vegas
Year
1983
Drugs demonstrated
Papaverine and phentolamine
First-hand memoir author
Laurence Klotz, BJU International (2005)
Significance
First effective pharmacologic ED therapy publicly described

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Giles Brindley & the 1983 Las Vegas Demonstration. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Brindley, intracavernosal smooth-muscle relaxant work1983-1986

    Established that direct injection of papaverine/phentolamine reliably induces erection

  • Klotz memoir, BJU International2005

    First-hand published account documenting the 1983 demonstration